Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) EBT Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EBT Margin for 7 consecutive years, with 1338.75% as the latest value for Q2 2025.

  • On a quarterly basis, EBT Margin changed N/A to 1338.75% in Q2 2025 year-over-year; TTM through Dec 2025 was 4656.19%, a 754384.0% decrease, with the full-year FY2025 number at 4526.01%, down 691323.0% from a year prior.
  • EBT Margin was 1338.75% for Q2 2025 at Outlook Therapeutics, down from 2777.76% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1338.75% in Q2 2025 to a low of 1338.75% in Q2 2025.